A Measured Approach to Vena Cava Filter Use-Respect Rather Than Regret.
Sign Up to like & getrecommendations! Published in 2017 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2016.3882
Abstract: Is there enough evidence to support the use of inferior vena cava filters?—Yes. There is a strong effort among many physicians to avoid the use of inferior vena cava filters (IVCFs) in the treatment of… read more here.
Keywords: therapy; benefit; vena cava; use ... See more keywords
Statins for Primary Cardiovascular Disease Prevention: Time to Curb Our Enthusiasm.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA internal medicine"
DOI: 10.1001/jamainternmed.2022.3204
Abstract: In the US, more than 126 million adults have been diagnosed with cardiovascular disease (CVD).1 Reducing the morbidity and mortality associated with CVD is a public health imperative. Accordingly, considerable resources and effort have been… read more here.
Keywords: prevention; cause mortality; risk; benefit ... See more keywords
Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.47375
Abstract: Key Points Question What patient characteristics are associated with benefit from treatment with COVID-19 convalescent plasma (CCP)? Findings This prognostic study of 2287 patients hospitalized with COVID-19 identified a combination of baseline characteristics that predict… read more here.
Keywords: benefit; treatment; convalescent plasma; treatment benefit ... See more keywords
Examination of Differences in Nonmedical Supplemental Benefit Coverage for Dual-Eligible Enrollees in Medicare Advantage Plans in 2021
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.35161
Abstract: This cross-sectional study uses Medicare Advantage benefit package data for 2021 to examine differences in the coverage of nonmedical supplemental benefits—such as transportation services and food and meal assistance—for dual-eligible enrollees with health-related social needs. read more here.
Keywords: dual eligible; eligible enrollees; medicare advantage; benefit ... See more keywords
Is Lung Cancer Screening Reaching the People Who Are Most Likely to Benefit?
Sign Up to like & getrecommendations! Published in 2022 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2022.43171
Abstract: Lung cancer remains the leading cause of cancer death in the US, largely because most patients have advanced, incurable disease at the time of diagnosis. Lung cancer screening with low-dose computed tomography (LDCT) therefore has… read more here.
Keywords: lung cancer; lung; cancer screening; benefit ... See more keywords
Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: A Meta-analysis of Randomized Clinical Trials.
Sign Up to like & getrecommendations! Published in 2019 at "JAMA oncology"
DOI: 10.1001/jamaoncol.2019.0818
Abstract: Importance The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) have independently published value frameworks. To date, whether the clinical benefit scoring algorithms from these framework were intended to… read more here.
Keywords: benefit; difference; framework; survival ... See more keywords
Dynamic changes in circulating tumor DNA assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC
Sign Up to like & getrecommendations! Published in 2023 at "Molecular Oncology"
DOI: 10.1002/1878-0261.13409
Abstract: Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis are the main therapeutic option for patients with advanced non‐small cell lung cancer (NSCLC) without a druggable oncogenic alteration. Nevertheless, only a portion of patients benefit from… read more here.
Keywords: whole genome; checkpoint inhibitors; genome sequencing; benefit ... See more keywords
Survival benefit stratification of partial nephrectomy versus non‐surgical treatment in elderly patients with T1a renal cell carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Medicine"
DOI: 10.1002/cam4.5580
Abstract: Renal cell carcinoma (RCC) of stage T1a has been proven to be of low‐grade malignancy and mostly affects elderly individuals with relatively limited life expectancy. However, research on the survival benefit of surgery relative to… read more here.
Keywords: cell carcinoma; renal cell; survival benefit; non surgical ... See more keywords
Discovery of Nonracemic Amisulpride to Maximize Benefit/Risk of 5‐HT7 and D2 Receptor Antagonism for the Treatment of Mood Disorders
Sign Up to like & getrecommendations! Published in 2021 at "Clinical Pharmacology and Therapeutics"
DOI: 10.1002/cpt.2282
Abstract: In contrast to the dose‐occupancy relationship in the treatment of schizophrenia, the minimal effective level of dopamine receptor 2 (D2R) blockade for antipsychotics in the treatment of bipolar depression is unknown. Lower doses aimed at… read more here.
Keywords: d2r blockade; d2r; benefit; treatment ... See more keywords
Liver transplantation for hepatocellular carcinoma through the lens of transplant benefit
Sign Up to like & getrecommendations! Published in 2017 at "Hepatology"
DOI: 10.1002/hep.28998
Abstract: One of the crucial objectives in medicine is to assess and quantify the benefit of a therapeutic approach to a given clinical condition in order to avoid delivering potentially harmful treatments (when the risk is… read more here.
Keywords: liver transplantation; waiting list; benefit; transplant benefit ... See more keywords
Vessels That Encapsulate Tumor Clusters (VETC) Pattern Is a Predictor of Sorafenib Benefit in Patients with Hepatocellular Carcinoma
Sign Up to like & getrecommendations! Published in 2018 at "Hepatology"
DOI: 10.1002/hep.30366
Abstract: Sorafenib is the most recommended first‐line systemic therapy for advanced hepatocellular carcinoma (HCC). Yet there is no clinically applied biomarker for predicting sorafenib response. We have demonstrated that a vascular pattern, named VETC (Vessels that… read more here.
Keywords: benefit; vetc; sorafenib benefit; tumor clusters ... See more keywords